Harold M Chung MD
Hematologic Oncology, Myeloproliferative Disorder Hematology-Oncology
Associate Professor, Internal Medicine, Virginia Commonwealth University, Medical College of Virginia School of Medicine
Join to View Full Profile
1300 E Marshall StNorth Hospital - 10th Floor BMT UnitRichmond, VA 23298
Phone+1 804-828-4360
Dr. Chung is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Harold Chung is an Associate Professor at VCU Medical Center in Richmond, VA, specializing in Hematology with subspecialties in Hematologic Oncology and Myeloproliferative Disorders. He completed his medical education at the University of Oklahoma College of Medicine and pursued a residency in Internal Medicine at the University of Iowa Hospitals and Clinics, followed by a fellowship in Hematology and Medical Oncology at Virginia Commonwealth University Health System. Dr. Chung possesses experience in non-Hodgkin lymphoma, hematopoietic stem cell transplantation, acute myeloid leukemia, and multiple myeloma. He has contributed to various publications in reputable journals and participated in clinical trials such as the Rituxan/BEAM vs Bexxar/BEAM in Autologous Hematopoietic Stem Cell Transplant for Non-Hodgkin's Lymphoma. He has also received CMS Meaningful Use Stage 1 Certification from Cerner Corporation.
Education & Training
Virginia Commonwealth University Health SystemFellowship, Hematology and Medical Oncology, 1997 - 2000
University of Iowa Hospitals and ClinicsResidency, Internal Medicine, 1994 - 1997
University of Oklahoma College of MedicineClass of 1994
Certifications & Licensure
VA State Medical License 1997 - 2026
IA State Medical License 1994 - 1998
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification Cerner Millennium Powerchart, Cerner Millennium FirstNet, Cerner Millennium ProFile, Health Sentry, Healthe Exchange, Cerner Healthe Record, IQHealth and P2 Sentinel (Powered by Sensage), Cerner Corporation, 2013-2015
- CMS Meaningful Use Stage 1 Certification PowerChart, FirstNet, HealthSentry and P2 Sentinel, Cerner Corporation, 2013-2015
Clinical Trials
- Rituxan/BEAM vs Bexxar/BEAM in Autologous Hematopoietic Stem Cell Transplant for Non-Hodgkin's Lymphoma (BMTCTN0401) Start of enrollment: 2005 Dec 01
Publications & Presentations
PubMed
- 19 citationsManaging post allograft relapse of myeloid neoplasms: azacitidine and donor lymphocyte infusions as salvage therapy.John Preston Claiborne, Dipankar Bandyopathyay, Catherine H. Roberts, Kelly G. Hawks, May Aziz
Leukemia & Lymphoma. 2019-05-03 - 3 citationsThe influence of lymphoid reconstitution kinetics on clinical outcomes in allogeneic stem cell transplantation.David J. Kobulnicky, Roy T. Sabo, Shashank Sharma, Ali S. Shubar Ali, Kristen M. Kobulnicky
Leukemia & Lymphoma. 2018-04-04 - 18 citationsLow-dose splenic irradiation prior to hematopoietic cell transplantation in hypersplenic patients with myelofibrosisNoah S. Kalman, Nitai D. Mukhopadhyay, Catherine H. Roberts, Harold M. Chung, William B. Clark
Leukemia & Lymphoma. 2017-05-31
Journal Articles
- Treatment of Acute Fibrinous Organizing Pneumonia Following Hematopoietic Cell Transplantation with EtanerceptK Miller, W B Clark, J M McCarty, A A Toor, H M Chung, Nature
Press Mentions
A Lifesaving Gift From 4,000 Miles Away: Cancer Survivor Meets Bone Marrow DonorJune 16th, 2025
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
